

## ERRATUM

# Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

KE Baker, LM Wood, M Whittaker and MJ Curtis

*British Journal of Pharmacology* (2006) **149**, 966. doi:10.1038/sj.bjp.0706958; published online 16 October 2006

**Correction to:** *British Journal of Pharmacology* (2006) **149**, 269–276. doi:10.1038/sj.bjp.0706846

Due to a typesetting error, the QT interval was incorrectly defined as the 'quantitative transmission (QT) interval' in

the Abbreviation section and in column 2 on page 269. The correct definition should remain as QT interval.

The typesetters would like to apologise for this error.